UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases 762,953 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 49.4% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,307,178 shares of the company's stock after acquiring an additional 762,953 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.31% of Roivant Sciences worth $26,625,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of the business. Cetera Advisors LLC bought a new stake in Roivant Sciences during the first quarter valued at $758,000. Teachers Retirement System of The State of Kentucky acquired a new stake in Roivant Sciences during the first quarter worth approximately $398,000. DNB Asset Management AS increased its holdings in Roivant Sciences by 6.4% in the second quarter. DNB Asset Management AS now owns 56,022 shares of the company's stock worth $592,000 after purchasing an additional 3,386 shares in the last quarter. SG Americas Securities LLC acquired a new position in Roivant Sciences in the second quarter valued at approximately $472,000. Finally, ORG Partners LLC bought a new position in shares of Roivant Sciences during the 2nd quarter worth approximately $106,000. Institutional investors own 64.76% of the company's stock.

Insider Transactions at Roivant Sciences

In other Roivant Sciences news, CEO Matthew Gline sold 1,983,257 shares of the business's stock in a transaction dated Monday, September 23rd. The shares were sold at an average price of $11.79, for a total value of $23,382,600.03. Following the transaction, the chief executive officer now directly owns 17,870,543 shares in the company, valued at $210,693,701.97. The trade was a 9.99 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Eric Venker sold 100,000 shares of the stock in a transaction that occurred on Wednesday, November 20th. The shares were sold at an average price of $11.32, for a total transaction of $1,132,000.00. Following the transaction, the chief operating officer now directly owns 606,525 shares of the company's stock, valued at $6,865,863. This represents a 14.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 3,677,309 shares of company stock worth $43,283,184 in the last 90 days. Insiders own 7.90% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on ROIV shares. HC Wainwright reiterated a "buy" rating and issued a $18.00 price objective on shares of Roivant Sciences in a research note on Wednesday, November 13th. Bank of America increased their price objective on shares of Roivant Sciences from $12.00 to $12.50 and gave the stock a "neutral" rating in a research report on Wednesday, September 11th. Finally, Cantor Fitzgerald reissued an "overweight" rating on shares of Roivant Sciences in a research note on Thursday, September 19th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $17.93.

Roivant Sciences Stock Performance

ROIV traded down $0.08 during mid-day trading on Thursday, reaching $12.03. 1,338,021 shares of the stock were exchanged, compared to its average volume of 5,804,780. Roivant Sciences Ltd. has a 1 year low of $9.48 and a 1 year high of $13.06. The company has a 50 day moving average price of $11.79 and a two-hundred day moving average price of $11.40. The stock has a market capitalization of $8.76 billion, a PE ratio of 2.14 and a beta of 1.25.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.